Wells Fargo analyst Stephen Baxter raised the firm’s price target on Universal Health (UHS) to $259 from $249 and keeps an Overweight rating on the shares following quarterly results. Overall, modestly higher EBITDA estimates and rolling fully to 2027 estimates offsets a material increase in the odds of enhanced exchange subsidies expiring in the firm’s price target framework, Wells says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Boeing upgraded, Charter downgraded: Wall Street’s top analyst calls
- Universal Health price target raised to $267 from $242 at Mizuho
- Universal Health upgraded to Outperform from Market Perform at Raymond James
- Universal Health price target raised to $231 from $206 at RBC Capital
- Universal Health price target raised to $302 from $280 at UBS